The company has received strong support from key opinion leaders in developing CAN10 for AD and will test it in a subset of patients where targeting of other pathways has failed, it states. This indication will complement CAN10’s lead indication, hidradenitis suppurativa (HS) and align with the project’s initial focus on inflammatory dermatological diseases.

The clinical study will be a pilot Phase 2 study that can start in parallel with the HS trial with data expected within 12 months of study initiation.

“It is clear that the potential of CAN10 includes targeting inflammatory diseases, where activation of very broad inflammatory pathways challenges the specific targeting of individual cytokines. Therefore, we believe that positioning CAN10 for treatment of resistant atopic dermatitis, where a significant unmet medical need remains, can benefit many people,” says Morten Lind Jensen, Chief Medical Officer of Cantargia.

CAN10

CAN10 is an antibody against IL1RAP designed to potently inhibit the activity of the pro-inflammatory and disease promoting cytokines of the IL-1-family, namely IL-1, IL-33 and IL-36. CAN10 is currently being evaluated in a phase 1 clinical trial with safety as the primary objective. The phase 2 study in the lead indication HS is expected to start towards the end of the year.